Nattokinase for heart health in people with high cholesterol
Part of Heart & circulation, Hormones & metabolism clinical trials.
This trial tests whether nattokinase, a natural enzyme, can reduce inflammation and improve heart health in people with high cholesterol or high triglycerides. If you have elevated LDL or triglycerides, you may be eligible even if you are already taking cholesterol medication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You have high LDL cholesterol (over 160 mg/dL) and/or high triglycerides (over 150 mg/dL)
- You may also be included if you have low HDL cholesterol (under 40 for men, under 50 for women), even if you are already on cholesterol medication
- You cannot have diabetes, autoimmune disease, active infection, cancer, or AIDS
- You cannot be pregnant
- You cannot be taking blood thinners, antibiotics, or certain catabolic drugs, and you cannot be allergic to corn or soy starch
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, CTX310, for people with persistently high levels of fats (triglycerides) and cholesterol that have not improved with standard treatments. It aims to see if the drug is safe and tolerable.
This trial studies whether buckwheat husk extract can improve certain heart-related measurements in people with mildly high blood pressure. It may help lower cardiovascular risk factors by affecting things like blood pressure.
This study tests whether two types of omega-3s (EPA and DHA) help improve HDL (good cholesterol) and reduce blood clot risk in people with high triglycerides and low HDL cholesterol.
This trial tests whether ANKASCIN 568-P products can improve blood cholesterol levels (like LDL and HDL) in people with mild “lipid” (cholesterol/fat) imbalance. It may help by lowering “bad” cholesterol and improving balance, especially if you’re not taking cholesterol-lowering medicine right now.
This trial studies how well long-term cholesterol-lowering treatment works in people who recently had a heart attack (STEMI or NSTEMI). It may help your care team understand which patients benefit most and how treatment should be continued safely.
This Phase 2 trial studies whether adding NAD+ can reduce heart muscle injury around scheduled heart surgery. It may help protect the heart (and possibly kidneys) in people considered higher risk for complications.
Hear when a new Cardiovascular Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.